期刊
CELLULAR AND MOLECULAR LIFE SCIENCES
卷 77, 期 4, 页码 677-703出版社
SPRINGER BASEL AG
DOI: 10.1007/s00018-019-03299-8
关键词
Anticancer therapy; DNA repair inhibition; Synthetic lethality
资金
- Worldwide Cancer Research Grant [16/1217]
- Greek General Secretariat for Research and Technology
- Hellenic Foundation for Research and Innovation (HFRI) Grant [472-EpiNotch]
- Horizon 2020 [732309, 801347]
DNA damage response, DNA repair and genomic instability have been under study for their role in tumor initiation and progression for many years now. More recently, next-generation sequencing on cancer tissue from various patient cohorts have revealed mutations and epigenetic silencing of various genes encoding proteins with roles in these processes. These findings, together with the unequivocal role of DNA repair in therapeutic response, have fueled efforts toward the clinical exploitation of research findings. The successful example of PARP1/2 inhibitors has also supported these efforts and led to numerous preclinical and clinical trials with a large number of small molecules targeting various components involved in DNA repair singularly or in combination with other therapies. In this review, we focus on recent considerations related to DNA damage response and new DNA repair inhibition agents. We then discuss how immunotherapy can collaborate with these new drugs and how epigenetic drugs can rewire the activity of repair pathways and sensitize cancer cells to DNA repair inhibition therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据